232 related articles for article (PubMed ID: 34493659)
1. MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex.
Llabata P; Torres-Diz M; Gomez A; Tomas-Daza L; Romero OA; Grego-Bessa J; Llinas-Arias P; Valencia A; Esteller M; Javierre BM; Zhang X; Sanchez-Cespedes M
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34493659
[TBL] [Abstract][Full Text] [Related]
2. Multi-Omics Analysis Identifies MGA as a Negative Regulator of the MYC Pathway in Lung Adenocarcinoma.
Llabata P; Mitsuishi Y; Choi PS; Cai D; Francis JM; Torres-Diz M; Udeshi ND; Golomb L; Wu Z; Zhou J; Svinkina T; Aguilera-Jimenez E; Liu Y; Carr SA; Sanchez-Cespedes M; Meyerson M; Zhang X
Mol Cancer Res; 2020 Apr; 18(4):574-584. PubMed ID: 31862696
[TBL] [Abstract][Full Text] [Related]
3. MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1.
Romero OA; Torres-Diz M; Pros E; Savola S; Gomez A; Moran S; Saez C; Iwakawa R; Villanueva A; Montuenga LM; Kohno T; Yokota J; Sanchez-Cespedes M
Cancer Discov; 2014 Mar; 4(3):292-303. PubMed ID: 24362264
[TBL] [Abstract][Full Text] [Related]
4. Loss of MGA repression mediated by an atypical polycomb complex promotes tumor progression and invasiveness.
Mathsyaraja H; Catchpole J; Freie B; Eastwood E; Babaeva E; Geuenich M; Cheng PF; Ayers J; Yu M; Wu N; Moorthi S; Poudel KR; Koehne A; Grady W; Houghton AM; Berger AH; Shiio Y; MacPherson D; Eisenman RN
Elife; 2021 Jul; 10():. PubMed ID: 34236315
[TBL] [Abstract][Full Text] [Related]
5. Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression.
Si J; Yu X; Zhang Y; DeWille JW
Mol Cancer; 2010 Apr; 9():92. PubMed ID: 20426839
[TBL] [Abstract][Full Text] [Related]
6. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.
Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J
Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536
[TBL] [Abstract][Full Text] [Related]
7. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.
Borromeo MD; Savage TK; Kollipara RK; He M; Augustyn A; Osborne JK; Girard L; Minna JD; Gazdar AF; Cobb MH; Johnson JE
Cell Rep; 2016 Aug; 16(5):1259-1272. PubMed ID: 27452466
[TBL] [Abstract][Full Text] [Related]
8. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
[TBL] [Abstract][Full Text] [Related]
9. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.
Szczepanski AP; Zhao Z; Sosnowski T; Goo YA; Bartom ET; Wang L
Genome Med; 2020 Jul; 12(1):63. PubMed ID: 32669118
[TBL] [Abstract][Full Text] [Related]
10. MAX Functions as a Tumor Suppressor and Rewires Metabolism in Small Cell Lung Cancer.
Augert A; Mathsyaraja H; Ibrahim AH; Freie B; Geuenich MJ; Cheng PF; Alibeckoff SP; Wu N; Hiatt JB; Basom R; Gazdar A; Sullivan LB; Eisenman RN; MacPherson D
Cancer Cell; 2020 Jul; 38(1):97-114.e7. PubMed ID: 32470392
[TBL] [Abstract][Full Text] [Related]
11. Mga, a dual-specificity transcription factor that interacts with Max and contains a T-domain DNA-binding motif.
Hurlin PJ; Steingrìmsson E; Copeland NG; Jenkins NA; Eisenman RN
EMBO J; 1999 Dec; 18(24):7019-28. PubMed ID: 10601024
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer.
Kelenis DP; Rodarte KE; Kollipara RK; Pozo K; Choudhuri SP; Spainhower KB; Wait SJ; Stastny V; Oliver TG; Johnson JE
Cancer Res; 2022 Sep; 82(17):3058-3073. PubMed ID: 35748745
[TBL] [Abstract][Full Text] [Related]
13. The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells.
Lafita-Navarro MC; Liaño-Pons J; Quintanilla A; Varela I; Blanco R; Ourique F; Bretones G; Aresti J; Molina E; Carroll P; Hurlin P; Romero OA; Sanchez-Céspedes M; Eisenman RN; Delgado MD; León J
J Biol Chem; 2020 Feb; 295(7):2001-2017. PubMed ID: 31919096
[TBL] [Abstract][Full Text] [Related]
14. Polycomb group ring finger protein 6 suppresses Myc-induced lymphomagenesis.
Tanaskovic N; Dalsass M; Filipuzzi M; Ceccotti G; Verrecchia A; Nicoli P; Doni M; Olivero D; Pasini D; Koseki H; Sabò A; Bisso A; Amati B
Life Sci Alliance; 2022 Aug; 5(8):. PubMed ID: 35422437
[TBL] [Abstract][Full Text] [Related]
15. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.
Schaub FX; Dhankani V; Berger AC; Trivedi M; Richardson AB; Shaw R; Zhao W; Zhang X; Ventura A; Liu Y; Ayer DE; Hurlin PJ; Cherniack AD; Eisenman RN; Bernard B; Grandori C;
Cell Syst; 2018 Mar; 6(3):282-300.e2. PubMed ID: 29596783
[TBL] [Abstract][Full Text] [Related]
16. Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis.
Diolaiti D; McFerrin L; Carroll PA; Eisenman RN
Biochim Biophys Acta; 2015 May; 1849(5):484-500. PubMed ID: 24857747
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
[TBL] [Abstract][Full Text] [Related]
18. Oligopeptides impairing the Myc-Max heterodimerization inhibit lung cancer cell proliferation by reducing Myc transcriptional activity.
D'Agnano I; Valentini A; Gatti G; Chersi A; Felsani A
J Cell Physiol; 2007 Jan; 210(1):72-80. PubMed ID: 16998799
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer.
Hokari S; Tamura Y; Kaneda A; Katsura A; Morikawa M; Murai F; Ehata S; Tsutsumi S; Ishikawa Y; Aburatani H; Kikuchi T; Miyazono K; Koinuma D
Mol Oncol; 2020 Feb; 14(2):277-293. PubMed ID: 31782890
[TBL] [Abstract][Full Text] [Related]
20. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer.
Ishii J; Sato H; Sakaeda M; Shishido-Hara Y; Hiramatsu C; Kamma H; Shimoyamada H; Fujiwara M; Endo T; Aoki I; Yazawa T
Pathol Int; 2013 Mar; 63(3):158-68. PubMed ID: 23530560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
